Synairgen announces leadership shakeup amid program advance

Published 16/05/2025, 07:24
Synairgen announces leadership shakeup amid program advance

SOUTHAMPTON, UK - Synairgen PLC (LON:SYNG), a firm specializing in respiratory drug development, today disclosed significant changes to its executive team, including a new CEO appointment, set to take effect from July 1, 2025. Richard Marsden will resign as CEO and board member but will continue to provide strategic guidance as a part-time Board Advisor. Joseph Colliver, the current CFO, will ascend to the CEO role, bringing a diverse business and financial background to the company’s leadership.

Mark Parry-Billings, who has served as Non-Executive Chairman since October 2024, will assume the position of Executive Chairman on the same date. His expanded role aims to utilize his extensive experience in pharma and biotech R&D to further advance Synairgen’s core program, particularly its investigational SNG001 treatment for viral pneumonia in mechanically-ventilated patients.

Dr. Parry-Billings expressed gratitude for Marsden’s two decades of leadership and contributions to Synairgen, noting the importance of the transition for the company’s future. He also conveyed confidence in Colliver’s capabilities to lead Synairgen through its next phase of development.

These leadership transitions come at a pivotal time for Synairgen, as the company focuses on addressing the high unmet medical needs of patients with viral pneumonia. The information is based on a press release statement from Synairgen PLC.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.